Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC111
- Development stage
- Preclinical
- Lead developer
- Scinai Immunotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PC111 is a first-in-class, fully human monoclonal antibody targeting soluble Fas Ligand (sFasL), developed for the treatment of rare skin diseases such as pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). It acts by inhibiting keratinocyte apoptosis and acantholysis, offering a non-immunosuppressive approach compared to current treatments like steroids and Rituximab. PC111 has shown efficacy in preventing blister formation in both in vitro and in vivo models.
- Other names
- Soluble-FasL monoclonal antibodysFasL mAbSoluble-FasL mAb
02
Targets
FASLG (Fas ligand)
Beyond the preview
Go deeper on PC111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC111.